Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia

Chemico-Biological Interactions

Volumn 184, Issue 1-2, 2010, Pages 50-57

  Qian, Zhijian ^a   Joslin, John M ^a   Tennant, Thelma R ^a   Reshmi, Shalini C ^a   Young, David J ^a   Stoddart, Angela ^a   Larson, Richard A ^a   Le Beau, Michelle M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cytogenetic analysis; Haploinsufficiency; Leukemogenesis; Therapy related myeloid leukemia; Tumor suppressor genes

Indexed keywords

ALKYLATING AGENT; ALPHA CATENIN; APC PROTEIN; BUB1 RELATED PROTEIN; CYCLIN A2; CYCLIN DEPENDENT KINASE 1; CYCLIN E; CYCLIN E2; EARLY GROWTH RESPONSE FACTOR 1; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MYC PROTEIN; NUCLEAR RECEPTOR NUR77; NUCLEOPHOSMIN; PEPTIDES AND PROTEINS; PROTEIN CTNNA1; PROTEIN FHL2; PROTEIN RPS14; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EVI1; TRANSCRIPTION FACTOR GFI1B; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CD34 SELECTION; CELL CYCLE REGULATION; CHROMOSOME 12P; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 18; CHROMOSOME 20Q; CHROMOSOME 3Q; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME 7Q; CHROMOSOME DELETION; CHROMOSOME LOSS; CYTOGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HEMATOPOIESIS; HUMAN; KARYOTYPE; MOLECULAR MODEL; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROTEIN EXPRESSION; THERAPY EFFECT; TRISOMY 8;

ANIMALS; CYTOGENETIC ANALYSIS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASMS, SECOND PRIMARY;

EID: 77950629000     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.11.025     Document Type: Article

References (38)

1. Godley L.A., Larson R.A. Therapy-related myeloid leukemia. Semin. Oncol. 2008, 35:418-429.
2. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Harris N.L., Le Beau M.M., Hellström-Lindberg E., Tefferi A., Bloomfield C.D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
3. Allan J.M., Travis L.B. Mechanisms of therapy-related carcinogenesis. Nat. Rev. Cancer 2005, 5:943-955.
4. Smith S.M., Le Beau M.M., Huo D., Karrison T., Sobecks R.M., Anastasi J., Vardiman J.W., Rowley J.D., Larson R.A. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003, 102:43-52.
5. Rowley J.D., Golomb H.M., Vardiman J.W. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 1981, 58:759-767.
6. Pedersen-Bjergaard J., Philip P. Cytogenetic characteristics of therapy-related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome: correlation with clinical data for 61 consecutive cases. Br. J. Haematol. 1987, 66:199-207.
7. Chromosome analysis of 63 cases of secondary nonlymphoid blood disorders: a cooperative study, Groupe Francais de Cytogenetique Hematologique. Cancer Genet. Cytogenet. 1984, 12:95-104.
8. Pedersen-Bjergaard J., Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991, 78:1147-1148.
9. Knight J.A., Skol A.D., Shinde A., Hastings D., Walgren R.A., Shao J., Tennant T.R., Banerjee M., Allan J.M., Le Beau M.M., Larson R.A., Graubert T.A., Cox N.J., Onel K. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009, 113:5575-5582.
10. Side L.E., Curtiss N.P., Teel K., Kratz C., Wang P.W., Larson R.A., Le Beau M.M., Shannon K.M. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer 2004, 39:217-223.
11. Bacher U., Haferlach T., Kern W., Haferlach C., Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007, 92:744-752.
12. Chen C.Y., Lin L.I., Tang J.L., Ko B.S., Tsay W., Chou W.C., Yao M., Wu S.J., Tseng M.H., Tien H.F. RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br. J. Haematol. 2007, 139:405-414.
13. Falini B., Nicoletti I., Martelli M.F., Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+AML): biologic and clinical features. Blood 2007, 109:874-885.
14. Shiseki M., Kitagawa Y., Wang Y.H., Yoshinaga K., Kondo T., Kuroiwa H. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Leukemia Lymphoma 2007, 48:2141-2144.
15. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J. Clin. Oncol. 2001, 19:1405-1413.
16. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003, 17:1813-1819.
17. Leone G., Pagano L., Ben-Yehuda D., Voso M.T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007, 92:1389-1398.
18. Qian Z., Fernald A.A., Godley L.A., Larson R.A., Le Beau M.M. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:14925-14930.
19. Gao Q., Horwitz M., Roulston D., Hagos F., Zhao N., Freireich E.J., Golomb H.M., Olopade O.I. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer 2000, 28:164-172.
20. Lai F., Godley L.A., Joslin J., Fernald A.A., Liu J., Espinosa R., Zhao N., Pamintuan L., Till B.G., Larson R.A., Qian Z., Le Beau M.M. Transcript map and comparative analysis of the 1.5Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 2001, 71:235-245.
21. Graubert T.A., Payton M.A., Shao J., Walgren R.A., Monahan R.S., Frater J.L., Walshauser M.A., Martin M.G., Kasai Y., Walter M.J. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 2009, 4:e4583.
22. Shannon K.M., Le Beau M.M. Cancer: hay in a haystack. Nature 2008, 451:252-253.
23. Santarosa M., Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim. Biophys. Acta 2004, 1654:105-122.
24. Zhao N., Stoffel A., Wang P.W., Eisenbart J.D., Espinosa R., Larson R.A., Le Beau M.M. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5Mb and preparation of a PAC-based physical map. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:6948-6953.
25. Fairman J., Chumakov I., Chinault A.C., Nowell P.C., Nagarajan L. Physical mapping of the minimal region of loss in 5q- chromosome. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7406-7410.
26. Boultwood J., Fidler C., Strickson A.J., Watkins F., Gama S., Kearney L., Tosi S., Kasprzyk A., Cheng J.F., Jaju R.J., Wainscoat J.S. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002, 99:4638-4641.
27. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., Raza A., Root D.E., Attar E., Ellis S.R., Golub T.R. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
28. Joslin J.M., Fernald A.A., Tennant T.R., Davis E.M., Kogan S.C., Anastasi J., Crispino J.D., Le Beau M.M. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007, 110:719-726.
29. Sportoletti P., Grisendi S., Majid S.M., Cheng K., Clohessy J.G., Viale A., Teruya-Feldstein J., Pandolfi P.P. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008, 111:3859-3862.
30. Qian Z., Chen L., Fernald A.A., Williams B.O., Le Beau M.M. A critical role for Apc in hematopoietic stem and progenitor cell survival. J. Exp. Med. 2008, 205:2163-2175.
31. Liu T.X., Becker M.W., Jelinek J., Wu W.S., Deng M., Mikhalkevich N., Hsu K., Bloomfield C.D., Stone R.M., DeAngelo D.J., Galinsky I.A., Issa J.P., Clarke M.F., Look A.T. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat. Med. 2007, 13:78-83.
32. Sukhatme V.P., Cao X.M., Chang L.C., Tsai-Morris C.H., Stamenkovich D., Ferreira P.C., Cohen D.R., Edwards S.A., Shows T.B., Curran T.A., Le Beau M.M., Adamson E.D. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 1988, 53:37-43.
33. Baron V., Adamson E.D., Calogero A., Ragona G., Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006, 13:115-124.
34. Min I.M., Pietramaggiori G., Kim F.F., Passegué E., Stevenson K.E., Wagers A.J. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell 2008, 10:380-391.
35. Fenske T.S., McMahon C., Edwin D., Jarvis J.C., Cheverud J.M., Minn M., Mathews V., Bogue M.A., Province M.A., McLeod H.L., Graubert T.A. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res. 2006, 66:5029-5038.
36. Wolff L., Koller R., Hu X., Anver M.R. A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms. J. Virol. 2003, 77:4965-4971.
37. Laslo P., Spooner C.J., Warmflash A., Lancki D.W., Lee H.J., Sciammas R., Gantner B.N., Dinner A.R., Singh H. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 2006, 126:755-766.
38. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H., Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002, 99:1909-1912.